Search

The article discusses the medicine Metformin, which is used for the treatment of type 2 diabetes (T2D) and is effective for obese patients. Particular focus is given to the abnormalities in patients with T2D which impacts the incretin hormones and hence incretin-based therapies are used as an alternative treatment including monotherapy, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 inhibitors.

The article discusses the findings by U.S. Food and Drug Administration (FDA) and the European Medicines Agency regarding a study by Johns Hopkins University School of Medicine researchers claiming that several incretin-based drugs including sitagliptin cause pancreatitis or pancreatic cancer.

The article discusses the treatments for patients with type 2 diabetes mellitus (T2DM). It highlights dipeptidyl peptidase IV (DPP IV) inhibitor drug, a newly discovered treatment for T2DM because it can degrade incretin peptides and metabolize other physiologic peptides. It also notes the use of angiotensin-converting enzyme (ACE) inhibitors as T2DM therapy, but there are increasing concerns about the side-effects ACE, particularly angioedema.

The article reports on the plans of the U.S. Food and Drug Administration (FDA) to study the impact of incretin mimetics on pancreatitis and cancer risk.